|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Verapamil#Adult Indications and Dosage]] |
| {{Verapamil}}
| |
| {{CMG}}; {{AE}} {{AK}}
| |
| | |
| ==INDICATIONS AND USAGE==
| |
| CALAN tablets are indicated for the treatment of the following:
| |
| | |
| ===Angina===
| |
| | |
| 1-Angina at rest including:
| |
| —
| |
| Vasospastic ([[Prinzmetal's variant]]) angina
| |
| —
| |
| [[Unstable angina|Unstable]] (crescendo, pre-infarction) [[Unstable angina|angina]]
| |
| | |
| 2-[[Chronic stable angina]] (classic effort-associated angina)
| |
| | |
| ===Arrhythmias===
| |
| | |
| 1-In association with digitalis for the control of ventricular rate at rest and during stress in patients with chronic [[atrial flutter]] and/or [[atrial fibrillation]](see [[Verapamil hydrochloride tablet warnings and precautions|WARNINGS: Accessory bypass tract]])
| |
| | |
| 2-Prophylaxis of repetitive[[ paroxysmal supraventricular tachycardia]]
| |
| | |
| ===Essential hypertension===
| |
| | |
| CALAN is indicated for the treatment of [[hypertension]], to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily [[strokes ]]and [[myocardial infarctions]]. These benefits have been seen in controlled trials of [[antihypertensive]] drugs from a wide variety of pharmacologic classes including this drug.
| |
| | |
| Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, [[antithrombotic ]]therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
| |
| | |
| Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.
| |
| | |
| Elevated [[systolic pressure|systolic]] or [[diastolic pressure ]]causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of [[severe hypertension]] can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with [[diabetes]] or [[hyperlipidemia]]), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.
| |
| | |
| Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on [[angina]], [[heart failure]], or [[diabetic kidney disease]]). These considerations may guide selection of therapy.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = CALAN (VERAPAMIL HYDROCHLORIDE) TABLET, FILM COATED [G.D. SEARLE LLC DIVISION OF PFIZER INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=55d5f933-42ff-4c80-a102-0ccb7f76b082#nlm34090-1 | publisher = | date = | accessdate = }}</ref>==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |